Long-term toxicities of selective estrogen-receptor modulators and antiaromatase agents

ONCOLOGY

Volumn 17, Issue 5, 2003, Pages 652-659

  Mortimer, Joanne E ^a   Urban, Janice H ^b  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE; AROMATASE INHIBITOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADULT; AGE; AGED; BREAST TUMOR; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MIDDLE AGED; MORTALITY; PATHOLOGY; POSTMENOPAUSE; PREMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONG-TERM CARE; MIDDLE AGED; NEOPLASM STAGING; POSTMENOPAUSE; PREMENOPAUSE; RALOXIFENE; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SURVIVAL RATE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 0141610998     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) Trialists' group: Anastro- zole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002.
2. Ettinger B, Lack DM, Mitlak BH, et al: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA 282:637-645, 1999.
3. Gnant M, Hausmaninger H, Samonigg H, et al: Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin ( ± zolendronate as adjuvant threatment for hormone receptor-positive premenopausal breast cancer: Results of a randomized multicenter trial (abstract 12). Breast Cancer Res Treat 76(suppl 1):S30, 2002.
4. Goss PE, Cheung AM, Lowery C: Comparison of the effects of exemestane, 17- hydroexemestane and letrozole on bone and lipid metabolism in the ovariectomized rat (abstract 415). Breast Cancer Res Treat 76(suppl 1):S107, 2002.
5. Chang J, Powles TJ, Ashley SE, et al: The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. Ann Oncol 7:671-675, 1996.
6. Delmas PD, Bjamason NH, Mitlak BH, et al: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal wornen. N Engl J Med 337:1641-1647, 1997.
7. Reis SE, Costantino JP, Wickerham L, et al: Cardiovascular effects of tamoxifen in women with and without heart disease: Breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. J Natl Cancer Inst 93:16-21,2001.
8. Cummings SR, Eckert S, Krueger KA, et al: The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. JAMA 281:2189-2197, 1999.
9. Lippman ME, Krueger KA, Eckert S, et al: Indicators of lifetime estrogen exposure: Effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants. J Clin Oncol 19:3111-3116, 2001.
10. Day R, Ganz PA, Costantino JP, et al: Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-l Study. J Clin Oncol 17:2659-2669, 1999.
11. Ernst T, Chang L, Cooray D, et al: The effects of tamoxifen and estrogens on brain metabolism in elderly women. J Natl Cancer Inst 94:592-597, 2002.
12. Yaffe K, Krueger K, Sarkar S, et al: Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med 344:1207-1213, 2001.